Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Completed · Phase 3 · NCT03440385
Conditions: Crohn Disease
At a glance
- Research payments reported, 2025
- $52,028
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 606
About the trial
- Sponsor
- Celgene
- Tested
- Ozanimod (drug), Placebo (other)
- Dates
- Started 2018-03-07; completion 2023-11-21
- Results posted
- Yes
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
From ClinicalTrials.gov, last updated 2024-12-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $52,028 in research payments for this study in 2025 (5 payments).
Products named: Zeposia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Heba N. Iskandar, M.D. Gastroenterology · Atlanta, GA
- David B. Rausher, M.D. Specialist · Decatur, GA
- Paul M. Hendrix, M.D. Gastroenterology · Idaho Falls, ID
- Christopher M. Johnson, M.D. Gastroenterology · Temple, TX
- Larry E. Clark JR., M.D. Gastroenterology · Lynchburg, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Atlanta Center for Gastroenterology, PC $27,345
- Grand Teton Research Group $12,720
- Baylor Research Institute $7,635
- Emory University Hospital, GA $2,600
- Gastroenterology Associates of Central Virginia $1,728
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.